149 related articles for article (PubMed ID: 36870689)
1. Dynamic Changes in Peripheral Systemic Immunity Markers During Chemotherapy in HER2-negative Advanced Breast Cancer.
Masuda T; Ueo H; Okumura Y; Kai Y; Ando Y; Masuguchi K; Kitagawa M; Kitagawa A; Hayashi N; Tsuruda Y; Hisamatsu Y; Suehiro S; Ohmura H; Fujiyoshi K; Tanaka F; Mimori K
Cancer Genomics Proteomics; 2023; 20(2):182-194. PubMed ID: 36870689
[TBL] [Abstract][Full Text] [Related]
2. Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer.
Nakamoto S; Ikeda M; Kubo S; Yamamoto M; Yamashita T; Notsu A
Sci Rep; 2021 Mar; 11(1):6328. PubMed ID: 33737682
[TBL] [Abstract][Full Text] [Related]
3. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
Araki K; Ito Y; Fukada I; Kobayashi K; Miyagawa Y; Imamura M; Kira A; Takatsuka Y; Egawa C; Suwa H; Ohno S; Miyoshi Y
BMC Cancer; 2018 Oct; 18(1):982. PubMed ID: 30326862
[TBL] [Abstract][Full Text] [Related]
4. Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin.
Su MX; Lin HW; Nguyen HTH; Lin TC; Chen CJ; Wang HC; Wu CT; Wu YC; He GY; Liu LC; Huang CH
BMC Cancer; 2024 Feb; 24(1):195. PubMed ID: 38347468
[TBL] [Abstract][Full Text] [Related]
5. Utility of Follow-up With Absolute Lymphocyte Count in Patients Undergoing Eribulin Treatment for Early Detection of Progressive Advanced or Metastatic Breast Cancer.
Goto W; Kashiwagi S; Takada K; Asano Y; Morisaki T; Shibutani M; Tanaka H; Hirakawa K; Ohira M
Anticancer Res; 2022 Feb; 42(2):939-946. PubMed ID: 35093893
[TBL] [Abstract][Full Text] [Related]
6. Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel.
Miyagawa Y; Araki K; Bun A; Ozawa H; Fujimoto Y; Higuchi T; Nishimukai A; Kira A; Imamura M; Takatsuka Y; Miyoshi Y
Clin Breast Cancer; 2018 Oct; 18(5):400-409. PubMed ID: 29605174
[TBL] [Abstract][Full Text] [Related]
7. Utility of the Absolute Lymphocyte Count and Neutrophil/Lymphocyte Ratio for Predicting Survival in Patients with Metastatic Breast Cancer on Eribulin: A Real-World Observational Study.
Ueno A; Maeda R; Kin T; Ito M; Kawasaki K; Ohtani S
Chemotherapy; 2019; 64(5-6):259-269. PubMed ID: 32305977
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of peripheral blood markers in soft tissue sarcoma patients treated with eribulin.
Ishihara S; Ogura K; Maejima A; Shimoi T; Sudo K; Kojima Y; Fukushima S; Osaki S; Kobayashi E; Iwata S; Matsui Y; Yonemori K; Kawai A
Jpn J Clin Oncol; 2023 Jun; 53(6):494-500. PubMed ID: 36989466
[TBL] [Abstract][Full Text] [Related]
9. Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors.
Kanaoka H; Nagahashi M; Atake Y; Hattori A; Bun A; Fukui R; Ozawa H; Fujimoto Y; Higuchi T; Natori K; Imamura M; Murase K; Takatsuka Y; Miyoshi Y
Anticancer Res; 2022 Oct; 42(10):4867-4878. PubMed ID: 36192009
[TBL] [Abstract][Full Text] [Related]
10. Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.
Asano Y; Kashiwagi S; Onoda N; Noda S; Kawajiri H; Takashima T; Ohsawa M; Kitagawa S; Hirakawa K
Ann Surg Oncol; 2016 Apr; 23(4):1104-10. PubMed ID: 26511266
[TBL] [Abstract][Full Text] [Related]
11. Validation of Systemic and Local Tumour Immune Response to Eribulin Chemotherapy in the Treatment of Breast Cancer.
Kashiwagi S; Asano Y; Goto W; Takada K; Morisaki T; Kouhashi R; Yabumoto A; Tanaka S; Takashima T; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2020 Jun; 40(6):3345-3354. PubMed ID: 32487630
[TBL] [Abstract][Full Text] [Related]
12. Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy.
Xu J; Ni C; Ma C; Zhang L; Jing X; Li C; Liu Y; Qu X
Clin Transl Oncol; 2017 Aug; 19(8):989-996. PubMed ID: 28247194
[TBL] [Abstract][Full Text] [Related]
13. Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types.
Morisaki T; Kashiwagi S; Asano Y; Goto W; Takada K; Ishihara S; Shibutani M; Tanaka H; Hirakawa K; Ohira M
World J Surg Oncol; 2021 Nov; 19(1):324. PubMed ID: 34775950
[TBL] [Abstract][Full Text] [Related]
14. Systemic immunity markers are associated with clinical outcomes of atezolizumab treatment in patients with triple-negative advanced breast cancer: a retrospective multicenter observational study.
Nakamoto S; Shien T; Itoh M; Yamamoto Y; Ohsumi S; Yoshitomi S; Hikino H; Miyoshi K; Notsu A; Taira N; Doihara H; Ikeda M
Clin Exp Med; 2023 Dec; 23(8):5129-5138. PubMed ID: 37904008
[TBL] [Abstract][Full Text] [Related]
15. Absolute Lymphocyte Count, Platelet-to-Lymphocyte Ratio, and Overall Survival in Eribulin-treated HER2-negative Metastatic Breast Cancer Patients.
Koyama Y; Kawai S; Uenaka N; Okazaki M; Asaoka M; Teraoka S; Ueda AI; Miyahara K; Kawate T; Kaise H; Yamada K; Ishikawa T
Cancer Diagn Progn; 2021; 1(5):435-441. PubMed ID: 35403160
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer.
Lim B; Song J; Ibrahim NK; Koenig KB; Chavez-MacGregor M; Ensor JE; Gomez JS; Krishnamurthy S; Caudle AS; Shaitelman SF; Whitman GJ; Valero V
Oncologist; 2021 Feb; 26(2):e230-e240. PubMed ID: 33140515
[TBL] [Abstract][Full Text] [Related]
17. Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan.
Takahashi M; Inoue K; Mukai H; Yamanaka T; Egawa C; Miyoshi Y; Sakata Y; Muramoto K; Ikezawa H; Matsuoka T; Tsurutani J
Breast Cancer; 2021 Jul; 28(4):945-955. PubMed ID: 33677779
[TBL] [Abstract][Full Text] [Related]
18. C-Reactive Protein and Absolute Lymphocyte Count Can Predict Overall Survival of Patients Treated With Eribulin.
Sata A; Fukui R; Miyagawa Y; Bun A; Ozawa H; Fujimoto Y; Higuchi T; Imamura M; Miyoshi Y
Anticancer Res; 2020 Jul; 40(7):4147-4156. PubMed ID: 32620664
[TBL] [Abstract][Full Text] [Related]
19. Absolute Lymphocyte Count as an Independent Prognostic Factor in Metastatic Breast Cancer: A Retrospective Study.
Sawa A; Bando H; Kamohara R; Takeuchi N; Terasaki A; Okazaki M; Iguchi-Manaka A; Hara H
Oncology; 2022; 100(11):591-601. PubMed ID: 36099888
[TBL] [Abstract][Full Text] [Related]
20. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
Schneeweiss A; Möbus V; Tesch H; Hanusch C; Denkert C; Lübbe K; Huober J; Klare P; Kümmel S; Untch M; Kast K; Jackisch C; Thomalla J; Ingold-Heppner B; Blohmer JU; Rezai M; Frank M; Engels K; Rhiem K; Fasching PA; Nekljudova V; von Minckwitz G; Loibl S
Eur J Cancer; 2019 Jan; 106():181-192. PubMed ID: 30528802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
